.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
Queensland Health
US Army
US Department of Justice
Dow
Citi
Baxter
Moodys
Deloitte

Generated: June 24, 2017

DrugPatentWatch Database Preview

PROMAZINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Promazine Hydrochloride, and when can generic versions of Promazine Hydrochloride launch?

Promazine Hydrochloride is a drug marketed by Watson Labs and is included in two NDAs.

The generic ingredient in PROMAZINE HYDROCHLORIDE is promazine hydrochloride. There are thirty-one drug master file entries for this compound. Additional details are available on the promazine hydrochloride profile page.

Summary for Tradename: PROMAZINE HYDROCHLORIDE

Patents:0
Applicants:1
NDAs:2
Bulk Api Vendors: see list33
Clinical Trials: see list2,244
Patent Applications: see list282
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PROMAZINE HYDROCHLORIDE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
PROMAZINE HYDROCHLORIDE
promazine hydrochloride
INJECTABLE;INJECTION084510-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Watson Labs
PROMAZINE HYDROCHLORIDE
promazine hydrochloride
INJECTABLE;INJECTION084517-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Teva
Deloitte
Baxter
Chinese Patent Office
Cipla
Novartis
Colorcon
US Department of Justice
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot